StockJungle
Latest
$CB Chubb wrote fourteen billion dollars of insurance this quarter and walked away from the business that did not pay — Chubb earned $6.82 per share on an 84% combined ratio while deliberately non-renewing mispriced property business. The underwriting culture is the moat. • $RVMD Pancreatic Cancer Just Got Its First Real Punch Against KRAS. The Survival Numbers Are Not Small. — Daraxonrasib delivered a hazard ratio of 0.40 in the Phase 3 RASolute 302 trial, nearly doubling median overall survival in previously treated metastatic pancreatic cancer. Gene rates RVMD a Buy. • $IDYA IDEAYA's Eye Cancer Drug Just Got the Biggest Stage in Oncology. The Scoreboard Looks Real. — IDEAYA's darovasertib combo cut progression risk 58% in the first randomized trial for HLA-A2-negative metastatic uveal melanoma. Now the full dataset heads to ASCO's main stage. • The SpaceX S-1 Is a Blueprint for a Civilization-Scale Company — SpaceX's now-public S-1 reveals $18.67B in revenue, a $1.75T target valuation, dual-class control for Musk, and a 30% retail allocation that could reshape the IPO market. • $TSLA Tesla's Robotaxi Just Went Unsupervised in Three Texas Cities. The Price War With Waymo Is Already Over. — Tesla launched fully driverless rides in Dallas and Houston, undercutting Waymo by 56% on price, with Cybercab mass production starting this month and seven cities targeted by June. • $CB Chubb wrote fourteen billion dollars of insurance this quarter and walked away from the business that did not pay — Chubb earned $6.82 per share on an 84% combined ratio while deliberately non-renewing mispriced property business. The underwriting culture is the moat. • $RVMD Pancreatic Cancer Just Got Its First Real Punch Against KRAS. The Survival Numbers Are Not Small. — Daraxonrasib delivered a hazard ratio of 0.40 in the Phase 3 RASolute 302 trial, nearly doubling median overall survival in previously treated metastatic pancreatic cancer. Gene rates RVMD a Buy. • $IDYA IDEAYA's Eye Cancer Drug Just Got the Biggest Stage in Oncology. The Scoreboard Looks Real. — IDEAYA's darovasertib combo cut progression risk 58% in the first randomized trial for HLA-A2-negative metastatic uveal melanoma. Now the full dataset heads to ASCO's main stage. • The SpaceX S-1 Is a Blueprint for a Civilization-Scale Company — SpaceX's now-public S-1 reveals $18.67B in revenue, a $1.75T target valuation, dual-class control for Musk, and a 30% retail allocation that could reshape the IPO market. • $TSLA Tesla's Robotaxi Just Went Unsupervised in Three Texas Cities. The Price War With Waymo Is Already Over. — Tesla launched fully driverless rides in Dallas and Houston, undercutting Waymo by 56% on price, with Cybercab mass production starting this month and seven cities targeted by June. •
Get in touch

Contact StockJungle

Real people read these emails. We answer the ones that need a response in a reasonable amount of time. If you have found an error in our research, we want to hear about it before anyone else does.

Updated April 21, 2026 · StockJungle archive

How to reach us

We do not have a phone queue. Email is the right channel for almost everything. Use the address that fits the question. The shorter and more specific the message, the faster the answer.

General questions and support

Email support@stockjungle.app for help with your account, billing, or any general question about how the site works. If your question is already answered on the FAQ, you will get there faster than we will.

Editorial corrections

Email corrections@stockjungle.app if you believe a piece of research contains an error of fact. Include the article URL and the specific claim you are correcting. We treat correction requests as priority work because nothing erodes trust faster than ignored errors.

Press

Email press@stockjungle.app for media inquiries, interview requests, or background on the platform. Please include your outlet, deadline, and the angle you are working on so we can route the request to the right person.

Partnerships

Email partnerships@stockjungle.app for collaborations, data licensing, or research distribution. We are selective. A short note describing the fit usually beats a long deck.

Response time

We aim to reply within a few business days. Editorial corrections move faster. Sales pitches and unsolicited demos move slower or not at all.

What not to email us about

Personal investment advice. We do not give it. Every piece of research on the site is general in nature and is not a recommendation for your situation. If you need personalized advice, please consult a qualified financial advisor.

Related reading